IV.c

Obliterative bronchiolitis (see also IVn)

(Fr: bronchiolite oblitérante). Pattern distinct from BOOP or AFOP (See section I). It is suspected when airflow obstruction is noted in the context of normal or hyperlucent lungs on chest radiographs and a mosaic or (less often) a tree-in-bud pattern on HRCT studies. HSCT and lung transplant recipients and victims of exposure to noxious gases including chlorine are prone to the development of this complicaton. PMID 20371529, 20441501, 20477273. See under pathology, as bronchiolitis is as the name implies a designation used in pathology

Last update : 16/12/2014
 

Causative drugs

18

Chemicals

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.j I - Interstitial/parenchymal lung disease
I.j - Exogenous lipoid pneumonia
I.af I - Interstitial/parenchymal lung disease
I.af - Chemical pneumonitis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
IV.q IV - Airway involvement
IV.q - Reactive airway dysfunction syndrome (RADS)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.s XI - Miscellaneous
XI.s - Death following inhalation of compound - Sniffing death
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XIV.a XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.a - Methemoglobinemia
XIV.b XIV - Hemoglobinopathies-Abnormal hemoglobins states (acquired)
XIV.b - Sulfhemoglobinemia
XV.x XV - Pulmonary pathology
XV.x - Path: Acute or subacute bronchiolitis (see also IVc, IVi)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVII.p XVII - Infections & related conditions
XVII.p - Lung abscess/abscesses (see also VIr)
3

Crack cocaine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.j II - Pulmonary edema - ARDS - Acute respiratory failure
II.j - Transient pulmonary opacities
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.e IV - Airway involvement
IV.e - Cough (acute, violent, explosive)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.d VIII - Upper, central, large airway involvement
VIII.d - Thermal (burns, frostbite), chemical, or caustic facial and/or airway injury
VIII.m VIII - Upper, central, large airway involvement
VIII.m - Drug foreign body in the airway
VIII.ac VIII - Upper, central, large airway involvement
VIII.ac - Retropharyngeal emphysema
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.aa XII - Cardiovascular involvement / toxicity
XII.aa - Arterial (aorta, limb) vasoconstriction and/or ischemia, acute
XII.ae XII - Cardiovascular involvement / toxicity
XII.ae - Aortic dissection
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.s XV - Pulmonary pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.bb XV - Pulmonary pathology
XV.bb - Path: Airway inflammation
XV.bj XV - Pulmonary pathology
XV.bj - Path: Alveolar carbonaceous material or deposits
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVIII.l XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.l - Eye catcher: Candy-cane esophagus
1

Herbals - Dietary, botanical therapy - Food

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.q II - Pulmonary edema - ARDS - Acute respiratory failure
II.q - Respiratory distress
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.w VIII - Upper, central, large airway involvement
VIII.w - Uvulitis, uvular edema
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.h XII - Cardiovascular involvement / toxicity
XII.h - Eosinophilic myocarditis
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.w XII - Cardiovascular involvement / toxicity
XII.w - Asystole
XII.ah XII - Cardiovascular involvement / toxicity
XII.ah - Tachycardia
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.z XV - Pulmonary pathology
XV.z - Path: Chronic obliterative broncholitis (see also IVc, IVn)
3

Mesalazine - Mesalamine (5-aminosalicylate)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.z XV - Pulmonary pathology
XV.z - Path: Chronic obliterative broncholitis (see also IVc, IVn)
XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement
3

Penicillamine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like) or flare of
XI.t XI - Miscellaneous
XI.t - Yellow nail syndrome
XV.z XV - Pulmonary pathology
XV.z - Path: Chronic obliterative broncholitis (see also IVc, IVn)
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
2

Rituximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.i II - Pulmonary edema - ARDS - Acute respiratory failure
II.i - Flash (fulminate) pulmonary edema
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
VII.g VII - Mediastinal involvement
VII.g - Hemomediastinum - Mediastinal hematoma
VIII.x VIII - Upper, central, large airway involvement
VIII.x - Opportunistic large airway infection (bacterial, fungal, viral)
IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.n X - Systemic conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.av X - Systemic conditions, syndromes and reactions
X.av - Hypogammaglobulinemia-Antibody deficiency (see under XVIIw)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1

Status post-hematopoietic stem cell (HSCT) or bone marrow transplantation (BMT)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.e II - Pulmonary edema - ARDS - Acute respiratory failure
II.e - Transfusion-related acute lung injury (TRALI or -ARDS)
II.n II - Pulmonary edema - ARDS - Acute respiratory failure
II.n - Engraftment syndrome
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.ap XV - Pulmonary pathology
XV.ap - Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
XV.bv XV - Pulmonary pathology
XV.bv - Path: pulmonary cytolytic thrombi
XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection
3

Talc (inhaled, sniffed, i.v., intrapleural)

I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.t I - Interstitial/parenchymal lung disease
I.t - Pneumoconiosis, talcosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.f II - Pulmonary edema - ARDS - Acute respiratory failure
II.f - Hypoxemia, low saturation (may occur in isolation)
IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn)
IV.i IV - Airway involvement
IV.i - Foreign body aspiration bronchiolitis
IV.m IV - Airway involvement
IV.m - Bronchial stenosis/stricture
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.r V - Pleural and/or pericardial involvement
V.r - Pleural mass or masses
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.g VI - Pulmonary vasculopathy
VI.g - Foreign body vasculopathy (Excipient lung disease)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.u XI - Miscellaneous
XI.u - Chronic chest pain/discomfort
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.q XV - Pulmonary pathology
XV.q - Path: Foreign body deposits/reaction
XV.s XV - Pulmonary pathology
XV.s - Path: Pneumoconiosis (silicosis, talcosis, talcoma)
XV.ag XV - Pulmonary pathology
XV.ag - Path: Foreign body embolism, microangiopathy, vasculopathy
XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or several nodules
XVI.ae XVI - Imaging
XVI.ae - Imaging: A pattern similar to progressive massive fibrosis (PMF)
XVIII.i XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.i - Eye-catcher: Tracer-avid pleural area or areas on PET-scan
XIX.k XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.k - BAL: Talc crystals in macrophages or lying free in BALF
1